Payment overview · 2025
General Payments
$201,125.15
248 reported records · 22 companies
Healthcare provider profile · identity verified
Peter Yuwei Chang, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology · WALTHAM, MA · NPI 1801107859
Verified facts
What the public records show
CMS Open Payments records show Peter Yuwei Chang, M.D. received $201,125.15 in general payments during 2025 across 248 reported records.
Mallinckrodt Hospital Products Inc. accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Acthar, Cequa, Lumigan, Miebo, Oxervate, Vyzulta, Xdemvy, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Lumigan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Simbrinza as an associated drug or biological on 1563 records involving 637 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Simbrinza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Prolensa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYZULTA as an associated drug or biological on 10850 records involving 5317 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vyzulta by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xiidra by this doctor in 2024.
Dompe US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OXERVATE as an associated drug or biological on 19540 records involving 9712 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Oxervate by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Actemra by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Acthar by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cequa as an associated drug or biological on 25765 records involving 9461 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Cequa by this doctor in 2024.
Tarsus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XDEMVY as an associated drug or biological on 46638 records involving 15254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xdemvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $109,594.13 | 54.5% | 107 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $48,431.57 | 24.1% | 27 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20,039.35 | 10.0% | 27 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $7,007.76 | 3.5% | 7 | 2025 |
| X4 Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6,000.00 | 3.0% | 1 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $5,899.38 | 2.9% | 10 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $1,680.00 | 0.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $706.39 | 0.3% | 27 | 2025 |
| Samsara Vision | Unresolved — no canonical attribution shown | $414.73 | 0.2% | 3 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $259.33 | 0.1% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $198.70 | 0.1% | 4 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $189.86 | 0.1% | 7 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $162.98 | 0.1% | 5 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $149.48 | 0.1% | 2 | 2025 |
| Astellas Pharma Global Development | Unresolved — no canonical attribution shown | $109.22 | 0.1% | 1 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $91.27 | 0.1% | 3 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $64.51 | 0.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.88 | 0.0% | 2 | 2025 |
| Neurotech Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.17 | 0.0% | 1 | 2025 |
| Thea Pharma Inc. | Unresolved — no canonical attribution shown | $21.72 | 0.0% | 1 | 2025 |
| Rayner Intraocular Lenses Limited | Unresolved — no canonical attribution shown | $20.02 | 0.0% | 1 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $14.70 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150,496.61 | 22 |
| Honoraria | $18,962.50 | 4 |
| Travel and Lodging | $10,601.19 | 42 |
| Consulting Fee | $8,680.00 | 4 |
| Food and Beverage | $7,884.85 | 174 |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,500.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $109,594.13 | 107 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc. | $48,385.43 | 26 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $16,637.44 | 15 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma Global Development, Astellas Pharma US Inc | $7,116.98 | 8 | 2025 |
Source payment records
|
|||||
| XOLREMDI Normalized: xolremdi |
Drug | X4 Pharmaceuticals, Inc. | $6,000.00 | 1 | 2025 |
Source payment records
|
|||||
| XIPERE Normalized: xipere |
Drug | Bausch & Lomb Americas Inc. | $4,685.05 | 5 | 2025 |
Source payment records
|
|||||
| YUTIQ Normalized: yutiq |
Drug | ANI Pharmaceuticals, Inc. | $2,978.01 | 4 | 2025 |
Source payment records
|
|||||
| Susvimo Normalized: susvimo |
Drug | Genentech USA, Inc., Genentech, Inc. | $1,811.70 | 4 | 2025 |
Source payment records
|
|||||
| Vabysmo Normalized: vabysmo |
Drug | Genentech USA, Inc., Genentech, Inc. | $1,747.00 | 4 | 2025 |
Source payment records
|
|||||
| ILUVIEN Normalized: iluvien |
Drug | ANI Pharmaceuticals, Inc. | $423.90 | 8 | 2025 |
Source payment records
|
|||||
| Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz) Normalized: implantable miniature telescope imt by dr isaac lipshitz |
Device | Samsara Vision | $414.73 | 3 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $413.84 | 15 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $259.33 | 5 | 2025 |
Source payment records
|
|||||
| OZURDEX Normalized: ozurdex |
Drug | ABBVIE INC. | $197.90 | 7 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $189.86 | 7 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $162.98 | 5 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $124.76 | 1 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $94.65 | 5 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $91.27 | 3 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $91.27 | 3 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $64.51 | 4 | 2025 |
Source payment records
|
|||||
| EYLEA Normalized: eylea |
Biological | Regeneron Healthcare Solutions, Inc. | $46.14 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| HYDRUS Microstent Normalized: hydrus microstent |
Device | Alcon Vision LLC | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| IYUZEH Normalized: iyuzeh |
Drug | Thea Pharma Inc. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Omidria Normalized: omidria |
Drug | Rayner Intraocular Lenses Limited | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ACTHAR acthar |
2025 | Acthar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Cequa cequa |
2025 | Cequa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUMIGAN lumigan |
2025 | Lumigan | 2024 | 43 | exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OXERVATE oxervate |
2025 | Oxervate | 2024 | 48 | exact normalized | Medicare Part D |
| VYZULTA vyzulta |
2025 | Vyzulta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XDEMVY xdemvy |
2025 | Xdemvy | 2024 | 11 | exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
43 | 18 |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Simbrinza open payments reported associated product |
CMS Open Payments — General Payments 1563 supporting records · 637 recipient NPIs · example record 1207357100 |
Simbrinza · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | VYZULTA open payments reported associated product |
CMS Open Payments — General Payments 10850 supporting records · 5317 recipient NPIs · example record 1254730226 |
Vyzulta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Dompe US, Inc. Exact reporting entity; no affiliate inference |
2025 | OXERVATE open payments reported associated product |
CMS Open Payments — General Payments 19540 supporting records · 9712 recipient NPIs · example record 1248849978 |
Oxervate · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Cequa open payments reported associated product |
CMS Open Payments — General Payments 25765 supporting records · 9461 recipient NPIs · example record 1250962431 |
Cequa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Tarsus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XDEMVY open payments reported associated product |
CMS Open Payments — General Payments 46638 supporting records · 15254 recipient NPIs · example record 1233825434 |
Xdemvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 171 | 58 |
| Prednisolone Acetate | Prednisolone Acetate | 156 | 85 |
| Brimonidine Tartrate | Brimonidine Tartrate | 150 | 47 |
| Methotrexate | Methotrexate Sodium | 133 | 37 |
| Timolol Maleate | Timolol Maleate | 130 | 41 |
| Latanoprost | Latanoprost | 104 | 42 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 80 | 24 |
| Valacyclovir | Valacyclovir Hcl | 73 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 25 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 65 | 35 |
| Bromfenac Sodium | Bromfenac Sodium | 63 | 24 |
| Humira(Cf) Pen | Adalimumab | 55 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 53 | 22 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 52 | 19 |
| Oxervate | Cenegermin-Bkbj | 48 | 13 |
| Celecoxib | Celecoxib | 43 | 12 |
| Lumigan | Bimatoprost | 43 | 18 |
| Prolensa | Bromfenac Sodium | 43 | 17 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 41 | 18 |
| Restasis | Cyclosporine | 41 | 20 |
| Prednisone | Prednisone | 34 | 19 |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 31 | suppressed |
| Remicade | Infliximab | 29 | suppressed |
| Acthar | Corticotropin | 27 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 27 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 25 | 16 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Fluorometholone | Fluorometholone | 21 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 19 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 17 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Travoprost | Travoprost | 16 | suppressed |
| Xiidra | Lifitegrast | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Brinzolamide | Brinzolamide | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Difluprednate | Difluprednate | 14 | suppressed |
| Actemra | Tocilizumab | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Miebo | Perfluorohexyloctane/Pf | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Bimatoprost | Bimatoprost | 11 | suppressed |
| Cequa | Cyclosporine | 11 | suppressed |
| Humira(Cf) | Adalimumab | 11 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Vyzulta | Latanoprostene Bunod | 11 | suppressed |
| Xdemvy | Lotilaner | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201,125.15 · 248 records | Mallinckrodt Hospital Products Inc. | ACTHAR, Cequa, Clareon PanOptix Pro, DEXTENZA, DURYSTA, EYLEA, EYLEA HD, HYDRUS Microstent, ILUVIEN, IYUZEH, Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz), Izervay, LUMIGAN, MIEBO, OXERVATE, OZURDEX, Omidria, PURIFIED CORTROPHIN GEL, RYZUMVI, Susvimo, TYRVAYA, UPLIZNA, VYZULTA, Vabysmo, XDEMVY, XIIDRA, XIPERE, XOLREMDI, YUTIQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Acthar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error